The Global Metabolomics Market size is projected to reach USD 4.1 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 13.4% during the forecast period. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, availability of government and private funding for metabolomics research, and ongoing innovations in metabolomics instruments are driving the growth of the global metabolomics industry.
Key Players:
Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Human Metabolome Technologies, Inc. (Japan), LECO Corporation (US), Metabolon, Inc. (US), Bio-Rad Laboratories (US), Scion Instruments (US), DANI Instruments S.p.A. (Italy), GL Sciences (Japan), SRI Instruments (US), Kore Technology Ltd. (UK), and JASCO, Inc. (US)
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900
Metabolomics market dynamics
Driver: Availability of government and private funding for metabolomics research
Metabolomic studies are gaining prominence in the life science industry as they help reveal the optimum level of specific metabolites associated with the onset/progression of a disease and the exposure or response to treatment. With the rising prevalence and mortality rate of life-threatening diseases, such as cancer and CVD, there is an increasing focus on novel approaches that can offer effective diagnosis and treatment of these diseases. As metabolomics is considered a novel approach with tremendous potential, additional research is being conducted in this field. Also, in recent years, the focus on metabolomic biomarkers has increased in drug development. As a result of these factors, government and private investments in metabolomics research is increasing.
According to a report by The Metabolomics Innovation Centre (TMIC), metabolomics has experienced tremendous growth since the last decade. High-impact metabolomic discoveries in several diseases, such as cancer, have increased investments in metabolomics facilities across the globe. For instance, in 2018, the US has invested more than USD 65 million in its Regional Comprehensive Metabolomics Resource Cores, while the US universities are believed to have invested an equal amount in establishing metabolomics core facilities across the country. Canada has invested more than USD 30 million in its metabolomics activities and infrastructure. These investments have helped catalyze the appearance of more than 80 university-based metabolomics facilities across North America over the past 8 years. In addition, Australia has invested more than USD 49 million in its Metabolomics Australia platform, the Netherlands has invested around USD 69 million into the Netherlands Metabolomics Centre, and the UK has invested over USD 45 million in establishing the Phenome Centre in the Imperial College London. Thus, the rising investments in metabolomics research in different countries are expected to fuel the growth of the metabolomics market during the forecast period.
Restraints: Issues related to data examination and processing
Metabolomics techniques produce a substantial volume of data as they create millions of data points per second over a 10-minute or more prolonged analysis. The continuous growth in the generation of high-volume heterogeneous data is increasing data complexity and it is becoming increasingly difficult to evaluate all these data points effectively. Moreover, due to the chemical diversity of small molecule metabolites, it is impossible to study the entire metabolome using a single analytical technique. As a result, the data produced is not only complex but also leads to a proportionate increase in the demand for physical storage, correct and rigorous analysis, and suitable software/databases for visualization. Thus, the high complexity of data generated during life science research and the difficulty in managing it is expected to hinder the growth of the metabolomics market.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=900
Opportunity: Biomarker development
Metabolomics is used to identify new biomarkers through bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for developing in-vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from specific treatments. Moreover, in the near future, identifying biomarkers related to safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the metabolomics market.
North America accounted for the largest share of the metabolomics market in 2019
North America, which includes the US and Canada, accounted for the largest share of the metabolomics market. The large share of the North America region can be attributed to the presence of major players operating in the metabolomics market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Recent Developments
- In 2020, Danaher Corporation acquired GE Healthcare’s Life Sciences business.
- In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fishers analytical systems with Agilent’s OpenLAb Chromatography Data System
- In 2020, Waters Corporation announced the establishment of Immerse Cambridge, a research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia and research to accelerate the next generation of scientific advancements.
- In 2020, Hitachi acquired the remaining shares of Hitachi High-Technologies billion and made it its subsidiary. This subsidiary will be responsible for the manufacturing of measuring and analytical equipment, along with the development of chipmaking equipment and industrial materials and systems.
Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=900
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com